Expert Panel Opinion Defers EU Market Entry For Tricuspid Valve Replacement System

Once again, an EU expert panel has challenged the adequacy of a notified body review of the manufacturer’s clinical evaluation report, clearly tightening up on high-risk device oversight.

Enlarged eye of tax inspector looking through magnifying glass, inspecting offshore company financial papers, documents and reports.

The expert panel specializing in the circulatory system has evaluated a notified body clinical assessment of a completely new class III implantable device used in cardiology, a tricuspid valve replacement system and called for more studies.

The product has no CE marking. Indeed this is the first tricuspid replacement system where a company has applied for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

11 Jul 2025

• By Amanda Maxwell

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

10 Jul 2025

• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

10 Jul 2025

• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

09 Jul 2025

• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.